CBIA Stock UPDATES Canopus Biopharma In (CBIA) 0.1000 09/13/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Canopus Biopharma In (CBIA) 0.1000 $CBIA

Canopus BioPharma Inc. Announces Results from Compassionate Study in Hepatitis C patients in China
PR Newswire - Tue Jul 01, 9:00AM CDT
Canopus BioPharma Inc. (OTC Pink: CBIA) today announced topline results from a Compassionate Clinical Trial in China, evaluating the twice daily oral administration of Mogroside IV (Mogrovir(TM)). Mogrovir(TM) is a Toll-like receptor agonist and stimulator of the patient's immune system. Mogrovir(TM) was administered orally in combination with Ribavirn (RBV), for the treatment of Genotype 1, treatment naive Hepatitis C (HCV) patients. The study showed a statistically significant result regarding the improvement of both liver function and increased blood platelet counts. A selection of patients in the trial also showed a statistically significant reduction in HCV viral-load levels, in the three month follow up period post-therapy. HCV Viral-load in these specific patients were approaching zero after a period of 180 days (90 days Mogrovir(TM) Treatment and 90 days follow-up). This fact confirmed the immune activation effects which are expected from the immune activation characteristics of Mogrovir(TM).

Periodontitis - Pipeline Review, H2 2013 Research Report
M2 - Fri Feb 21, 2:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/h4fxc9/periodontitis) has announced the addition of the "Periodontitis - Pipeline Review, H2 2013" report to their offering. 'Periodontitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Periodontitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Periodontitis. Scope - A snapshot of the global therapeutic scenario for Periodontitis. - A review of the Periodontitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Periodontitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Periodontitis Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Periodontitis - Therapeutics Assessment Drug Profiles trafermin - Drug Profile simvastatin - Drug Profile Asterias - Drug Profile Stem Cell Therapy For Osteoporosis And Bone Regeneration - Drug Profile C5a Receptor Antagonist - Drug Profile OPM-3023 - Drug Profile Drug For Biofilms - Drug Profile ANR Program for Periodontitis - Drug Profile POD CRC-OHS - Drug Profile Antibacterial Agent - Drug Profile Sharon-3000 - Drug Profile Drug For Periodontal Disease - Drug Profile Product Description Mechanism of Action R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Aphios Corporation Kaken Pharmaceutical Co., Ltd. CSL Limited NeoStem, Inc. Onepharm Research and Development GmbH Canopus BioPharma Incorporated Ensoltek Co., Ltd. OTR3 For more information visit http://www.researchandmarkets.com/research/h4...iodontitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Latest Rhinovirus Infection Pipeline Review
M2 - Tue Jan 28, 9:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/m5q9nz/rhinovirus) has announced the addition of the "Rhinovirus Infection - Pipeline Review, H2 2013" report to their offering. 'Rhinovirus Infection - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rhinovirus Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhinovirus Infection. Scope - A snapshot of the global therapeutic scenario for Rhinovirus Infection. - A review of the Rhinovirus Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rhinovirus Infection pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Therapeutics Development - Boehringer Ingelheim GmbH - Theraclone Sciences, Inc. - Canopus BioPharma Incorporated - Cocrystal Discovery, Inc. - Sealife PHARMA GMBH - Polyrizon Ltd. Drug Profiles - SLP-0904 - OBR-5-340 - CB-1600 - Drug For Rhinovirus Infection - SLP-1001 - Human Rhinovirus Program - PL-402 - Human Rhinovirus Inhibitors - Rhinovirus Program - KR-22809 - Amiloride Derivatives For more information visit http://www.researchandmarkets.com/research/m5q9nz/rhinovirus

Communal Clash Claims Two Lives in Enugu
by Christopher Isiguzo - All Africa Global Media - Fri Jan 17, 1:21AM CST
No fewer than two persons have been reported dead and eight others injured following a communal clash between two Enugu communities last Wednesday.

Oral Mucositis - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wgg6sd/oral_mucositis) has announced the addition of the "Oral Mucositis - Pipeline Review, H2 2013" report to their offering. 'Oral Mucositis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Oral Mucositis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oral Mucositis. Scope - A snapshot of the global therapeutic scenario for Oral Mucositis. - A review of the Oral Mucositis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Oral Mucositis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Oral Mucositis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Oral Mucositis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Daewoong Pharmaceutical Co., Ltd. Soligenix, Inc. BioAlliance Pharma SA Sucampo Pharmaceuticals, Inc. ActogeniX NV Alder Biopharmaceuticals Inc. Promedior, Inc. ProCertus BioPharm Inc. GliaMed, Inc. Avaxia Biologics, Inc. Canopus BioPharma Incorporated Nephrx Corporation Tosk, Inc. Laila Pharmaceuticals Pvt. Ltd. Applied Protein Sciences, LLC For more information visit http://www.researchandmarkets.com/research/wg..._mucositis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Periodontal Disease - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Those in the Dental Field
M2 - Wed Sep 04, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sp3kl2/periodontal) has announced the addition of the "Periodontal Disease - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Periodontal Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Periodontal Disease, complete with latest updates, and special features on late-stage and discontinued projects. Periodontal Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Periodontal Disease. - A review of the Periodontal Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Periodontal Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Aphios Corporation - Biomedical Development Corporation - CSL Limited - Canopus BioPharma Incorporated - Ensoltek Co., Ltd. - Kaken Pharmaceutical Co.,Ltd. - NeoStem, Inc. - Onepharm Research and Development GmbH - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/sp...eriodontal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Tuberculosis - Pipeline Review, H2 2013 Reviews Key Players Involved in the Therapeutic Development for Tuberculosis
M2 - Mon Sep 02, 11:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bnt58v/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Tuberculosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Tuberculosis, complete with latest updates, and special features on late-stage and discontinued projects. Tuberculosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Tuberculosis. - A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Tuberculosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AVI BioPharma Inc. - Achillion Pharmaceuticals, Inc. - Advinus Therapeutics Pvt. Ltd. - Archivel Farma S.L. - AstraZeneca PLC - B&C Biopharm - BT PHARMA - Canopus BioPharma Incorporated - Chimerix, Inc. - Crucell N.V. - Eli Lilly and Company - Ensoltek Co., Ltd. - EpiVax, Inc. - GlaxoSmithKline Inc. - GlaxoSmithKline plc - Hollis-Eden Pharmaceuticals, Inc. - ISA Pharmaceuticals B.V. - Immune Network Research Ltd. - ImmunoBiology Limited - ImmunoVaccine Technologies Inc. - Johnson & Johnson - Lipotek Pty Ltd - Medisyn Technologies, Inc. - MicuRx Pharmaceuticals, Inc. - Mondobiotech Holding AG - NeED Pharma s.r.l. - Okairos - Pharminox Limited - Piramal Healthcare Limited - Pt. Bio Farma - Recipharm AB - Sanofi-Aventis - Sequella, Inc. - Snowdon Inc. - Statens Serum Institut - Summit Corporation plc - TVAX Biomedical, LLC - Transgene SA - Vakzine Projekt Management GmbH - Vertex Pharmaceuticals Incorporated - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/bn...berculosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Periodontitis - Pipeline Review, H1 2013
M2 - Wed Jul 17, 10:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g2qfrh/periodontitis) has announced the addition of the "Periodontitis - Pipeline Review, H1 2013" report to their offering. 'Periodontitis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Periodontitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Periodontitis. Periodontitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Periodontitis. - A review of the Periodontitis prod

Mucositis - Pipeline Review, H1 2013 Report
M2 - Wed Jun 19, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3z2zdt/mucositis) has announced the addition of the "Mucositis - Pipeline Review, H1 2013" report to their offering. "Mucositis - Pipeline Review, H1 2013", provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mucositis, complete with latest updates, and special features on late-stage and discontinued projects. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Mucositis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Mucositis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identify

H3N2 Infection - Pipeline Review, H1 2013 Featuring 7 Key Companies and 9 Drug Profiles
M2 - Mon Apr 29, 4:21AM CDT
Research and Markets has announced the addition of the "H3N2 Infection - Pipeline Review, H1 2013" report to their offering. 'H3N2 Infection - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for H3N2 Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for H3N2 Infection. Scope - A snapshot of the global therapeutic scenario for H3N2 Infection. - A review of the H3N2 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the H3N2 Infection pipeline on the basis of route of

Canopus BioPharma Incorporated - Product Pipeline Review - 2012
M2 - Mon Feb 18, 3:33AM CST
Summary




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Marina del Rey's Travel Award Brings Fresh Attention

Updated Category News Views 86

A harbor town just got handed a useful little megaphone. On November 18, 2026, the Marina del Rey Tourism Board said Marina del Rey had been selected as a winner in Good Housekeeping's 2027 Travel Awards. That is not a quarterly earnings event, and nobody ought to dress it up as one. Still, in the visitor economy, recognition from a broad consumer publication can matter...

Continue Reading
ROHM's GaN PFC Chip Targets the Power-Supply Squeeze

Updated Category News Views 72

Power supplies are where a lot of sleek electronics quietly lose the plot, and ROHM is taking a proper swing at that problem. Its new BM85060FV is a totem-pole power factor correction controller built for gallium nitride, or GaN, high-frequency switching in AC-DC power supplies. The headline is not subtle: ROHM says a 300 to 500 W system using the chip can reach 99%...

Continue Reading
Royce Global Trust's Discount Is Still the Whole Debate

Updated Category News Views 7

A $3.03 gap is staring investors right in the face. As of October 31, 2026, Royce Global Trust carried a net asset value of $17.51 per share while the market price sat at $14.48. That works out to roughly a 17.3% discount to NAV, and with a closed-end fund, that discount is not some footnote shoved under the table. It is a major part of the return story, good or bad. The...

Continue Reading
Vail’s Board Fight Puts Strategy Under a Sharp Lens

Updated Category News Views 123

Fresh snow does not make a boardroom dispute disappear. Vail Resorts has put out an investor presentation ahead of its December 14, 2026 annual meeting, asking shareholders to support all nine of management’s director nominees on its white proxy card. That is the formal message. The real message is plainer: NYSE:MTN knows this election has become a test of whether...

Continue Reading
The Estate Bets Over $1 Billion on Luxury Longevity

Updated Category News Views 108

A billion-dollar wellness promise just wandered into the condominium market. The Estate by sbe says its first three branded residential developments carry combined real estate value above $1 billion and encompass more than 500 units. That is not pocket change, and it is certainly not a routine hotel-brand licensing exercise dressed up with scented candles and a cold...

Continue Reading
Brightstar Picks Warsop for Its Next CEO Chapter Ahead

Updated Category News Views 99

A Handoff With Plenty Riding on the Rails A lottery supplier changing captains is not usually fireworks, but this one deserves a hard look. Brightstar Lottery has named Thomas Warsop to replace Vince Sadusky as chief executive officer and board member effective January 1, 2027. Sadusky is retiring from both posts on that date. The company is telegraphing an orderly baton...

Continue Reading
Freedom Debt Relief Earns Service Recognition in 2026

Updated Category News Views 143

A Service Badge Carries Weight in a Rough Business Debt settlement is not a business where a pleasant phone voice alone gets the job done. People arrive carrying unsecured balances, anxiety, and usually a fair amount of distrust. That is why CNBC Select naming Freedom Debt Relief its “Best for Customer Service” is more meaningful than the usual chest-thumping...

Continue Reading
DSFederal Takes On USDA NIFA Grants System Support Work

Updated Category News Views 0

A Quiet Contract With Real Operational Weight Grant paperwork rarely gets anybody’s pulse racing, yet a busted grants system can gum up research money from coast to coast in a hurry. DSFederal has won work supporting the U.S. Department of Agriculture’s National Institute of Food and Agriculture, or NIFA, through its Grants Management and Reporting System, known as...

Continue Reading
SwitchBot's Black Friday Sale Tests Smart Home Demand

Updated Category News Views 112

Holiday gadget season is where clever home-tech pitches either earn their keep or gather dust in a warehouse. SwitchBot is coming into Black Friday 2026 with discounts of up to 50% on select products, running from November 19 through Cyber Monday on November 30. The lineup is broad enough to matter: decorative color E Ink frames, automated curtains and blinds, an indoor...

Continue Reading
Nike Locks In Chicago Marathon Partnership Through 2036 Deal

Updated Category News Views 13

Twenty-eight miles of pavement, training plans, and branded shoes are not a quarterly earnings release, but Nike just made a very long-term statement in Chicago. The company and the Bank of America Chicago Marathon have extended their partnership through 2036, preserving a relationship that began in 2008. For a brand rebuilding credibility with runners, that kind of...

Continue Reading

Top 5 Most Recently Viewed Articles

Bret Baier's Exclusive Interview with Trump on FOX Super Bowl Show

Updated Category News Views 296

Bret Baier's Exclusive Interview with President Donald Trump In a highly anticipated television event, Bret Baier, the chief political anchor for FOX News Channel (FNC), will engage in a significant one-on-one interview with President Donald Trump during the FOX Super Bowl LIX pregame show. This exclusive interview will air in the 3 PM/ET hour and is set to be a revealing...

Continue Reading
3D Systems Corporation Lawsuit Notification: What Investors Should Know

Updated Category News Views 169

3D Systems Corporation Lawsuit Overview The Gross Law Firm has issued a notice regarding an important class action lawsuit that involves shareholders of 3D Systems Corporation (NASDAQ: DDD). This legal action arises from allegations concerning misleading statements made by the company during a specific class period that could affect investors significantly. Understanding...

Continue Reading
5W PR Takes Charge of Marketing Strategies for Bedsure Pet

Updated Category News Views 191

5W PR Appointed as Agency of Record for Bedsure Pet Bedsure Pet, a leader in pet essentials, has recently welcomed 5W PR as their Agency of Record. This collaboration aims to elevate the brand's visibility and credibility in the competitive pet products market. About Bedsure Pet Products Bedsure Pet is celebrated for offering a wide range of high-quality pet products,...

Continue Reading
Itafos Enhances Financial Stability by Selling St George Shares

Updated Category News Views 155

Itafos Strengthens Financial Position Through Share Monetization HOUSTON, Itafos Inc. (TSX-V: IFOS) (OTCQX: ITFS) has made headlines with its recent strategic move to partially monetize its equity interest in St George Mining Limited. This transaction, framed within the context of a larger corporate strategy, was initially announced following the sale of the Araxá...

Continue Reading
Hawkeye Invest AS Expands Stake in PCI Biotech Holding ASA

Updated Category News Views 343

Hawkeye Invest AS Enhances its Investment in PCI Biotech Holding ASA In a significant move, Hawkeye Invest AS, under the leadership of Øystein Barmen, has increased its stake in PCI Biotech Holding ASA by acquiring an additional 240,000 shares. This latest purchase has elevated their total ownership to 2,000,000 shares, representing a noteworthy 5.36% of the total shares...

Continue Reading